Technoclone
Private Company
Funding information not available
Overview
Technoclone is a privately held, revenue-generating diagnostics company headquartered in Vienna, Austria, with a 37-year history in the coagulation diagnostics market. It has evolved from a research-focused entity producing monoclonal antibodies to a fully integrated IVD company with a global distribution network. Its core business includes a broad test portfolio for routine and specialty coagulation, a line of automated analyzers (Ceveron series), and a strong OEM component. The company is a technology leader in automated thrombin generation testing (TGA) and holds a unique position with its quenching technology for simultaneous specialty and routine testing.
Technology Platform
Integrated platform for hemostasis diagnostics, including proprietary automated analyzers (Ceveron series) with quenching technology for simultaneous routine and specialty testing, a broad portfolio of immuno, chromogenic, and clotting assays, and pioneering fully automated Thrombin Generation Assay (TGA) capabilities.
Opportunities
Risk Factors
Competitive Landscape
Technoclone competes in the niche but competitive hemostasis diagnostics segment against major players like Siemens Healthineers, Sysmex, Roche, and Werfen. Its differentiation lies in its deep specialization, integrated TGA automation, and the unique quenching technology of its Ceveron s100 analyzer, which offers a distinct workflow advantage for laboratories.